Multivirus-specific T-cell Transfer Post SCT vs AdV, CMV and EBV Infections (TRACE)

July 15, 2025 updated by: Tobias Feuchtinger

Treatment of Chemo-refractory Viral Infections After Allogeneic Stem Cell Transplantation With Multispecific T Cells Against CMV, EBV and AdV: A Phase III, Prospective, Multicentre Clinical Trial

Haematopoietic stem cell transplantation (HSCT) can expose patients to a transient but marked immunosuppression, during which viral infections are an important cause of morbidity and mortality. Adoptive transfer of virus-specific T cells is an attractive approach to restore protective T-cell immunity in patients with refractory viral infections after allogeneic HSCT. The aim of this Phase III trial is to confirm efficacy of this treatment in children and adults.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

For a growing number of patients suffering from various conditions as, e.g., haematological malignancies or diverse genetic disorders, haematopoietic stem cell transplantation (HSCT) or bone marrow transplantation offer the only possible curative options. However, HSCT is associated with three major risks: graft rejection, graft-versus-host disease (GvHD) and opportunistic, mostly viral, infections or reactivations resulting from delayed immune reconstitution. Delayed immune reconstitution, however, often is the direct result of the severe pre-transplantation conditioning treatment and T-cell depletion of the transplant necessary to fight the risks of graft rejection and GvHD. Therefore, the risk for life-threatening opportunistic, mostly viral, infections is increased in post-transplantation patients. The most common infections after HSCT are Cytomegalovirus (CMV), Epstein-Barr virus (EBV) and Adenovirus (AdV).

The standard treatment approach for viral infections/reactivations is chemotherapy which shows limited efficacy and does not restore immunity. Therefore, effective new treatment options are required for this condition.

Previous investigations have shown that sufficient T-cell immunity is essential for the control and prevention of viral reactivations and newly occurring infections after HSCT. The infusion of T-cells is therefore a promising new approach to treat immune-comprised patients. However, infusion with unselected T cells is associated with an increased risk for GvHD due to the high content of alloreactive T cells. A very promising approach to minimize this problem is to remove alloreactive T cells and enrich, isolate and purify virus-specific T cells.

This approach has been studied for nearly two decades and the data published up to date indicate that virus-specific T-cell responses after adoptive T-cell transfer protect against virus-related complications post HSCT and restore T-cell immunity, in particular for AdV-, CMV- and EBV-infections. Despite these promising results, virus-specific T-cell transfer is not yet translated into daily clinical practice due to the lack of prospective clinical trials confirming the efficacy of this treatment approach.

The overall goal of this Phase III, double-blind placebo-controlled study is to test efficacy of multivirus-specific T cells to bring this treatment method in clinical routine. Multivirus-specific T cells generated in this study will be directed against all three most common post-HSCT viral infections: AdV, CMV and EBV. Thus, T-cell immunity will be restored to fight and prevent new viral infections.

After an initial screening visit, patients eligible to participate in the study will be treated within 28 days after screening. Patients will be randomized in a 2:1 (treatment: placebo) ratio and receive a single infusion with either multivirus-specific T cells or placebo. Patients will be followed up on the day of treatment, 1 day after and 1, 2, 4, 8 and 15 weeks after treatment. Treatment success will be measured by assessing different parameters including symptoms, quality of life, viral load and T-cell immunity in blood samples.

Patients eligible to participate in this study are adult and paediatric patients who have received allogeneic stem cell transplantation and suffer from new or reactivated EBV, AdV or CMV infection refractory to standard antiviral treatment for two weeks. Patients from the six European countries Germany, Belgium, Netherlands, UK, France and Italy will be enrolled. In total 130 patients plus 19 screening failures are expected to participate in the study.

Study Type

Interventional

Enrollment (Estimated)

149

Phase

  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

  • Belgium
      • Brussels, Belgium, 1090
        • Recruiting
        • UZ Brussel
        • Contact:
        • Principal Investigator:
          • Ann De Becker, Dr.
      • Brussels, Belgium, 1000
        • Recruiting
        • Institut Jules Bordet (JBI)
        • Contact:
        • Principal Investigator:
          • Philippe Lewalle, Prof
      • Ghent, Belgium, 9000
        • Recruiting
        • Ghent Universal Hospital (UZG)
        • Principal Investigator:
          • Tessa Kerre, Prof
        • Contact:
      • Leuven, Belgium, 3000
        • Recruiting
        • UZ Leuven
        • Contact:
        • Principal Investigator:
          • Johan Maertens, Prof.
      • Liège, Belgium, 4000
        • Recruiting
        • Université de Liège (ULG)
        • Contact:
        • Principal Investigator:
          • Yves Beguin, Prof.
  • France
      • Lille, France, 59037
        • Recruiting
        • Hôpital Jeanne de Flandre, CHU Lille
        • Contact:
        • Principal Investigator:
          • Bénédicte Bruno, Dr.
      • Lyon, France, 69008
        • Recruiting
        • Institut d'Hématologie et Oncologie PEdiatrique (iHOPe)
        • Contact:
        • Principal Investigator:
          • Marie Ouachée-Chardin, Dr.
      • Nancy, France, 54035
        • Recruiting
        • Centre Hospitalier Régional Universitaire de Nancy (CHRU)
        • Contact:
        • Principal Investigator:
          • Maud D'Aveni-Piney, Dr.
      • Paris, France, 75019
        • Recruiting
        • Hôpital Robert Debré
        • Contact:
        • Principal Investigator:
          • Jean Hugues Dalle, Prof.
      • Paris, France, 75015
        • Recruiting
        • Hôpital Necker - Enfants Malades
        • Contact:
        • Principal Investigator:
          • Bendedicte Neven, Prof.
      • Paris, France, 75013
        • Recruiting
        • Hôpital de la Pitié-Salpêtrière
        • Contact:
        • Principal Investigator:
          • Stéphanie Nguyen Quoc, Prof.
  • Germany
      • Berlin, Germany, 13353
        • Recruiting
        • Charité Berlin (Campus Virchow-Klinikum) - Klinik für Pädiatrie mit Schwerpunkt Onkologie und Hämatologie
        • Contact:
        • Principal Investigator:
          • Johannes Schulte, Prof.
      • Dresden, Germany, 01307
      • Düsseldorf, Germany, 40225
        • Recruiting
        • Universitätsklinikum Düsseldorf - Klinik für Kinder-Onkologie, -Hämatologie und klinische Immunologie
        • Contact:
        • Principal Investigator:
          • Roland Meisel, Prof.
      • Essen, Germany, 45147
        • Recruiting
        • Universitätsklinikum Essen - Pädiatrische Hämatologie-Onkologie
        • Contact:
        • Principal Investigator:
          • Stefan Schönberger, Dr.
      • Freiburg, Germany, 79106
        • Recruiting
        • Universitätsklinikum Freiburg - Klinik für Pädiatrische Hämatologie und Onkologie
        • Contact:
        • Principal Investigator:
          • Brigitte Strahm, PD Dr.
      • Hannover, Germany, 30625
        • Recruiting
        • Medizinische Hochschule Hannover - Zentrum für Kinderheilkunde und Jugendmedizin
        • Contact:
        • Principal Investigator:
          • Britta Maecker-Kolhoff, Prof.
      • Leipzig, Germany, 04103
        • Recruiting
        • Universitäsklinikum Leipzig - Medizinische Klinik und Poliklinik I
        • Contact:
        • Principal Investigator:
          • Vladan Vucinic, Dr.
      • Munich, Germany, 80337
        • Recruiting
        • LMU Klinikum - Dr. v. Haunersches Kinderspital
        • Contact:
        • Principal Investigator:
          • Tobias Feuchtinger, Prof.
      • Munich, Germany, 80804
        • Recruiting
        • Klinikum rechts der Isar der Technischen Universität - Kinderklinik Schwabing
        • Contact:
        • Principal Investigator:
          • Irene Teichert von Lüttichau, PD Dr.
      • München, Germany, 81377
        • Recruiting
        • LMU Klinikum - Medizinische Klinik und Poliklinik III
        • Contact:
        • Principal Investigator:
          • Johanna Tischer, Dr.
      • München, Germany, 81675
        • Recruiting
        • Klinikum rechts der Isar der Technischen Universität - Klinik und Poliklinik für Innere Medizin III
        • Principal Investigator:
          • Mareike Verbeek, Dr.
        • Contact:
      • Regensburg, Germany, 93053
        • Recruiting
        • Universitätsklinikum Regensburg - Pädiatrische Hämatologie, Onkologie und Stammzelltransplantation
        • Contact:
        • Principal Investigator:
          • Jürgen Föll, Prof.
      • Tübingen, Germany, 72076
        • Recruiting
        • Universitätsklinikum Tübingen, Center for Pediatric Clinical Studies (CPCS)
        • Contact:
        • Principal Investigator:
          • Peter Lang, Prof.
      • Würzburg, Germany, 97080
        • Recruiting
        • Universitätsklinikum Würzburg - Medizinische Klinik und Poliklinik II & Zentrum Innere Medizin (ZIM)
        • Contact:
        • Principal Investigator:
          • Hermann Einsele, Prof.
      • Würzburg, Germany, 97080
        • Recruiting
        • Universitätsklinikum Würzburg - Pädiatrische Hämatologie, Onkologie und Stammzelltransplantation
        • Contact:
        • Principal Investigator:
          • Matthias Wölfl, Prof.
  • Italy
      • Rom, Italy, 00165
        • Recruiting
        • Ospedale Pediatrico Bambino Gesu (OPBG)
        • Contact:
        • Principal Investigator:
          • Franco Locatelli, Prof.
      • Turin, Italy, 10126
        • Recruiting
        • Ospedale Infantile Regina Margherita - Oncoematologie Pediatrica
        • Contact:
        • Principal Investigator:
          • Franca Fagioli, Prof.
  • Netherlands
      • Leiden, Netherlands, 2333
        • Recruiting
        • Leiden University Medical Centre (LUMC) - Department of Hematology
        • Contact:
        • Principal Investigator:
          • Peter van Balen, Dr.
  • Spain
      • Barcelona, Spain, 119-129
        • Recruiting
        • Vall d'Hebron Institute of Oncology (VHIO)
        • Contact:
        • Contact:
        • Principal Investigator:
          • María Laura Fox, Dr.
      • Madrid, Spain, 28046
        • Recruiting
        • Hospital Universitario La Paz
        • Contact:
        • Principal Investigator:
          • Antonio Pérez-Martinez, Dr.
      • Sevilla, Spain, 41013
      • Valencia, Spain, 46026
        • Recruiting
        • Hospital Universitario Politecnico La Fe
        • Contact:
        • Principal Investigator:
          • Juan Montoro Gómez, Dr.

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

3 years and older (Child, Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  1. Adult or paediatric patients (> 2 months of age) after allogeneic stem cell transplantation (SCT) (no time restrictions apply) suffering from new or reactivated CMV or EBV or AdV infection refractory to standard antiviral treatment for two weeks (defined as no decrease or insignificant decrease of less than 1log in viral load over two weeks) as confirmed by quantitative blood PCR analysis.
  2. Original HSCT-donor available with an immune response at least to the virus causing the therapy-refractory (=underlying) infection.
  3. Written informed consent given (patient or legal representative) prior to any study-related procedures.

Exclusion Criteria:

  1. Patient with acute GvHD > grade II or extensive chronic GvHD at the time of IMP transfer
  2. Patient receiving steroids (>1 mg/kg BW Prednisone equivalent) at Screening.
  3. Therapeutic donor lymphocyte infusion (DLI) from 4 weeks prior to IMP infusion until 8 weeks post IMP infusion. Prescheduled prophylactic DLI ≤3x105 T cells/kg BW in case of T-cell depleted HSCT is not considered an exclusion criterion.
  4. Patient with organ dysfunction or failure as determined by Karnofsky (patients >16 years) or Lansky (patients ≤16 years) score ≤30%
  5. Concomitant enrolment in another clinical trial interfering with the endpoints of this study
  6. Any medical condition which could compromise participation in the study according to the investigator's assessment
  7. Progression of underlying disease (disease that has led to the indication of HSCT, e.g. leukaemia) that will limit the life expectance below the duration of the study
  8. Second line or experimental antiviral treatment other than Ganciclovir/Valganciclovir, Foscarnet, Cidofovir and Rituximab until 8 weeks after IMP Infusion or prophylactic Treatment other than Aciclovir or Letermovir throughout the study except approved by sponsor
  9. Known HIV infection. In case patients do not have a negative HIV test performed within 6 months before enrolment in the study, HIV negativity has to be confirmed by a negative laboratory test.

  10. Female patient who is pregnant or breast-feeding. Female patient of child-bearing potential (i.e. post menarche and not surgically sterilized) or male patient of reproductive potential not willing to use an effective method of birth control from Screening until the last follow-up visit (FU6, Visit 8).

    Note: Women of childbearing potential must have a negative serum pregnancy test at study entry ≤7 days before IMP administration on Day 0. Acceptable birth control methods are hormonal oral contraceptive ('pill'), contraceptive injection or patch, intrauterine pessar or the combination of two barrier methods. The combination of female and male condomes is NOT acceptable. If the male partner is sterilized, no further contraceptive is required. Women of post-menopausal status (no menses for 12 months without an alternative medical cause) are also not required to use contraceptives during the study.

  11. Known hypersensitivity to iron dextran
  12. Patients unwilling or unable to comply with the protocol or unable to give informed consent.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Quadruple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Multivirus (CMV, EBV, AdV)-specific T cells

Allogeneic CD4+ and CD8+ T lymphocytes ex vivo incubated with synthetic peptides of the viral antigens of Cytomegalovirus, Adenovirus and Epstein-Barr Virus

Max dose:

  • HLA-matched (8/8) donors: 1.0 x 10e5 T cells/kg recipient BW
  • HLA-mismatched donors: 2.5 x 10e4 T cells/kg recipient BW

Min. dose:

- 10 T cells/kg recipient BW
Other: Multivirus (CMV, EBV, AdV)-specific T cells
Cell therapy product which is individually produced for each patient and administered via IV bolus injection.
Placebo Comparator: Sodium chloride
Suspension of multivirus-specific T cells in 20 mL of 0.9% NaCl + 0.5% HSA
Other: Multivirus (CMV, EBV, AdV)-specific T cells
Cell therapy product which is individually produced for each patient and administered via IV bolus injection.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Viral clearance
Time Frame: 8 weeks after treatment
Percentage of patients with viral clearance (defined as two consecutive negative PCRs) to determine efficacy of multispecific T-cell transfer in patients with chemo-refractory viral infections after allogeneic stem cell transplantation
8 weeks after treatment
Disease Progression
Time Frame: day 7 until week 8 after treatment
Percentage of patients with progression between Day 7 and Week 8 after T-cell Transfer to determine efficacy of multispecific T-cell transfer in patients with chemo-refractory viral infections after allogeneic stem cell transplantation
day 7 until week 8 after treatment

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Incidence of acute GvHD
Time Frame: 15 weeks after treatment
Incidence of newly occurring acute GvHD grade I from Day 0 to Week 8 and Week 15.
15 weeks after treatment
Incidence of chronic GvHD
Time Frame: 15 weeks after treatment
Incidence of chronic GvHD from Day 7 to Week 8 and to Week 15 after treatment.
15 weeks after treatment
Time to newly occuring GvHD
Time Frame: 15 weeks after treatment
Time to newly occurring acute and chronic GvHD.
15 weeks after treatment
Severity of GvHD
Time Frame: week 8 and 15 week after treatment
Severity of acute GvHD ≥ grade II until Week 8 and Week 15.
week 8 and 15 week after treatment
Incidence of acute toxicity
Time Frame: 15 minutes, 30 minutes, 2 hours and 4 hours post T-cell/placebo transfer
Acute maximum toxicity on the day of T-cell transfer evaluated by measuring vital signs prior to and at different times after the T-cell transfer from 1 hour prior to T-cell transfer to 4 hours post infusion.
15 minutes, 30 minutes, 2 hours and 4 hours post T-cell/placebo transfer
Severity of acute toxicity
Time Frame: 15 minutes, 30 minutes, 2 hours and 4 hours post T-cell/placebo transfer
Monitoring of adverse events infusion.
15 minutes, 30 minutes, 2 hours and 4 hours post T-cell/placebo transfer
Change in viral load of underlying viral infection
Time Frame: 8 weeks after treatment
Change in viral load of underlying viral infection as assessed by quantitative PCR analysis of peripheral blood; samples taken weekly from Day 7 to Week 8 after IMP transfer as compared to samples taken at Day 0.
8 weeks after treatment
Time to viral load change of underlying viral infection
Time Frame: 15 weeks after treatment
Time to 1 log change in viral load.
15 weeks after treatment
Percentage of viral decrease
Time Frame: 8 weeks after treatment
Percentage of patients with ≥1 log decrease in CMV, EBV or AdV viral load at Week 8.
8 weeks after treatment
Viral reactivations
Time Frame: 15 weeks after treatment
Number of reactivations of the underlying viral infection following initial viral clearance until end of follow-up.
15 weeks after treatment
Clinical response/resolution of symptoms of underlying viral infection
Time Frame: 8 weeks after treatment
Number of patients with reduction or clearance of clinical symptoms of underlyingviral infection from Day 7 to Week 8 after IMP transfer as compared to Day 0.
8 weeks after treatment
Overall survival
Time Frame: 15 weeks after treatment
Overall survival rate (OS): From Day 0 to end of follow-up.
15 weeks after treatment
Necessity of antiviral chemotherapy
Time Frame: Day 7 until Week 8
Number of days requiring antiviral chemotherapy after T-cell transfer from Day 7 to Week 8 after T-cell transfer.
Day 7 until Week 8
Duration of antiviral chemotherapy
Time Frame: 8 weeks after treatment
Time to last administration of defined antiviral medication or switch to prophylactic treatment from Day 0 to Week 8 after IMP transfer.
8 weeks after treatment
Incidence of viral infections other than underlying viral infection
Time Frame: 15 weeks
Number of new viral reactivations (CMV, AdV or EBV) other than the underlying viral infection per patient as assessed by PCR analysis and clinical symptoms throughout the study to evaluate the putative prophylactic effect of the treatment.
15 weeks
Days of hospitalization
Time Frame: 8 weeks
Number of days hospitalized after IMP transfer from Day 7 to Week 8.
8 weeks
Life quality in adults
Time Frame: Screening and Week 8.
EQ-5D for adult patients (≥18 years) at Screening and Week 8 to evaluate life quality in adults. A scale from 0 to 100 is used with 100 being best value and 0 the worst.
Screening and Week 8.
Life quality in adults
Time Frame: Screening and Week 8

FACT-BMT for adult patients (≥18 years) at Screening and Week 8 to evaluate life quality in adults.

The patients have to answer questions about their physicial, social, emotional and functional wellbeing. A scale from 0 to 4 is used with 0= not at all, 1= a little bit, 2=somewhat, 3=quite a bit, 4=very much.
Screening and Week 8
Life quality in children
Time Frame: Screening and Week 8

PEDS-QL for paediatric patients (<18 years) at Screening and Week 8 to evaluate life quality in children.

The patients and /or their parents have to answer questions about pain and hurt, fatigue and sleep, nausea, worry, Nutrition, thinking and communication.

A scale from 0 to 4 is used with 0=never a Problem, 1=almost never a problem, 2= sometimes a problem, 3=often a problem, 4= almost always a problem.
Screening and Week 8
Effect on the patient's T-cell phenotype in vivo
Time Frame: Screening until Week 15
T-cell phenotyping, samples taken at Screening, Day 0 and each visit from Day 7 to Week 15 after treatment.
Screening until Week 15
Effect on the patient's number of expanded T cells
Time Frame: Screening until Week 15
Analysis of virus-specific T cells: frequencies of in vivo expanded virus-specific T cells in peripheral blood samples taken at Screening, Day 0, Day 7 to Week 15 after treatment.
Screening until Week 15
Quality of the IMP and performance of the CliniMACS® Prodigy
Time Frame: Before IMP release (between Screening and Day 0)
Assessment of the cellular composition, in particular the percentage of IFN-gamma+ cells, in the IMP.
Before IMP release (between Screening and Day 0)
Evaluation of the drop-out rate
Time Frame: at Day 0 (planned treatment day)
Drop-out rate at Day 0 and reasons for drop-out.
at Day 0 (planned treatment day)
Time from inclusion to administration of the IMP
Time Frame: Screening until Day 0 (treatment day)
Number of days from Screening to Day 0 (day of IMP transfer) to evaluate the required time frame.
Screening until Day 0 (treatment day)
Adverse events
Time Frame: 15 weeks
Documentation of incidence, severity and type of adverse events from Day 0 to Week 8 and serious adverse events throughout the study to evaluate safety.
15 weeks
Physical examination
Time Frame: Screening to Week 8
Physical examinations will be conducted to identify possible clinically significant pathologies. These findings will be recorded at each visit. The Karnofsky/Lansky index will be included in the physical examination at Screening and at Week 8 only.
Screening to Week 8
Vital Sign - blood pressure
Time Frame: Screening to Week 8
supine systolic and diastolic blood preasure in mm Hg
Screening to Week 8
Vital Signs - heart rate
Time Frame: Screening to Week 8
The resting heart rate in beats/min
Screening to Week 8
Vital Signs - body temperature
Time Frame: Screening to Week 8
Body temperature in °C (aural)
Screening to Week 8
Vital Signs - body weight
Time Frame: Screening to Week 8
body weight in kg
Screening to Week 8
Vital Signs - respiratory rate
Time Frame: Screening to Week 8
respiratory rate in breaths/min.
Screening to Week 8
Incidence of abnormal laboratory values
Time Frame: Screening to Week 8

haemoglobin, leukocytes, thrombocytes, dirfferential blood count (neutrophil granulocytes, lymphocytes, monocytes and easinophil granulocytes), total and conjugated Bilirubin, C reactive Protein (CRP), creatinine, Alanin aminotransferase (ALT), Aspartate aminotransferase (AST), Gamma glutamyl Transferase (GGT), Lactate Dehydrase (LDH), Urea.

A list of normal ranges will be provided from each site.
Screening to Week 8
Concomitant medication until Week 8
Time Frame: 8 weeks after treatment
All concomitant medication will be recorded from Screening until Week 8. The generic name, indication, route of administration, dose/ unit, start and stop date or ongoing, way of application will be documented.
8 weeks after treatment
Concomitant medication until Week 15
Time Frame: 15 weeks after treatment

During follow-up Week 15, only antiviral therapy, immunosuppression and SAE-related concomitant medication as well as chemotherapy will be documented.

The generic name, indication, route of administration, dose/ unit, start and stop date or ongoing, way of application will be documented.

Cellular treatment also has to be documented as concomitant medication.
15 weeks after treatment

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Tobias Feuchtinger

Collaborators

Central Hospital, Nancy, France
European Commission
Vall d'Hebron Institute of Oncology
Simbec-Orion Group Ltd, Merthyr Tydfil, UK
Miltenyi Biotec B.V. & Co. KG, Bergisch Gladbach, Germany
Leiden University Medical Center, LUMC, Leiden, The Netherlands
Ghent University Hospital, UZG, Ghent, Belgium
Ospedale Pediatrico Bambino Gesù, OPBG, Rome, Italy
Newcastle University, UNEW, Newcastle, UK

Investigators

  • Principal Investigator: Tobias Feuchtinger, Prof, Medical Center - University of Freiburg

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

August 27, 2019

Primary Completion (Estimated)

March 1, 2028

Study Completion (Estimated)

September 1, 2028

Study Registration Dates

First Submitted

March 19, 2021

First Submitted That Met QC Criteria

April 1, 2021

First Posted (Actual)

April 6, 2021

Study Record Updates

Last Update Posted (Actual)

July 18, 2025

Last Update Submitted That Met QC Criteria

July 15, 2025

Last Verified

July 1, 2025

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • TRACE
  • 2018-000853-29 (EudraCT Number)
  • DRKS00018985 (Other Identifier: Deutsches Register Klinischer Studien)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on CMV Infection

Clinical Trials on Multivirus (CMV, EBV, AdV)-specific T cells

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Sri Lanka

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe